News

Under the terms of the agreement, in exchange for I.V.S. becoming a wholly-owned subsidiary of OphthaliX, OphthaliX will issue to the sellers and option holders of I.V.S. at

US Oncology Research and Cure Forward will work together to make personalized medicine more accessible and approachable in the community setting, reinforcing the cooperation that exists between physicians

SDC Nutrition said it is building on an existing relationship with former CEO of GNC Brazil, Juan Alonso, to market and distribute its sports nutrition brands in Latin

The company should now provide more information to NICE to make a final decision on the use of idelalisib in combination with rituximab for adults with chronic lymphocytic

In NHL, treatment with tazemetostat continues to demonstrate an encouraging profile with nine of 15 evaluable NHL patients achieving an objective response, including a partial response in the

The research collaboration will build on the company’s manufacturing protocol for its lead cancer program, CLBS20 (NBS20). All the parties will explore new techniques to further improve the

The Phase II Pathway Study’s primary efficacy outcome is the change in motor strength of the various muscle groups in the upper extremities innervated by the cervical spinal

The breakthrough therapy designation follows positive results from ARC001, which is the company’s randomized, double-blind, placebo-controlled Phase II trial of AR101 for desensitization treatment of peanut allergy. At

Glatopa is the first AP-rated substitutable generic designed to treat patients with relapsing-forms of multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation